{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T16:40:10Z","timestamp":1745512810234,"version":"3.40.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>5-Hydroxytryptamine 3 receptor antagonists (5-HT<jats:sub>3<\/jats:sub>RAs) and dexamethasone are recommended to prevent azacitidine-induced nausea and vomiting. In clinical practice, 5-HT<jats:sub>3<\/jats:sub>RAs or metoclopramide is often used without dexamethasone. In this study, we aimed to determine whether 5-HT<jats:sub>3<\/jats:sub>RAs or metoclopramide is more effective for suppressing nausea and vomiting during azacitidine-based chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study was a single-center retrospective observational study. Patients with myeloid malignancies receiving azacitidine-based regimens were treated with a 5-HT<jats:sub>3<\/jats:sub>RA (ramosetron or granisetron, <jats:italic>n<\/jats:italic>\u2009=\u200932) or metoclopramide (<jats:italic>n<\/jats:italic>\u2009=\u200918) for preventing nausea and vomiting. The occurrence of nausea and vomiting was assessed using total control (TC), complete control (CC), and complete response (CR) rates (chi-squared test), and the time to the first emetic episode or rescue medication (Cox proportional hazard regression analysis).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The 5-HT<jats:sub>3<\/jats:sub>RA group had significantly higher rates of TC, CC, and CR than the metoclopramide group (84% vs. 22%, 91% vs. 33%, and 91% vs. 33%, respectively). The time until the first emetic episode or rescue medication was also significantly longer in the 5-HT<jats:sub>3<\/jats:sub>RA group than in the metoclopramide group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>5-HT<jats:sub>3<\/jats:sub>RAs may prevent azacitidine-induced nausea and vomiting more effectively than metoclopramide.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Retrospectively registered.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40780-025-00444-3","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T15:58:40Z","timestamp":1745510320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of 5-hydroxytryptamine 3 receptor antagonists versus metoclopramide for preventing nausea and vomiting during azacitidine chemotherapy in patients with myelodysplastic syndromes or acute leukemia: a retrospective observational study"],"prefix":"10.1186","volume":"11","author":[{"given":"Yoshinori","family":"Wakasugi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ya","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"444_CR1","doi-asserted-by":"crossref","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472-8.","DOI":"10.1200\/JCO.2006.05.6382"},{"key":"444_CR2","doi-asserted-by":"crossref","unstructured":"Lindley CM, Hirsch JD, O\u2019Neill CV, Transau MC, Gilbert CS, Osterhaus JT. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992;1:331\u2009\u2212\u200940.","DOI":"10.1007\/BF00434947"},{"key":"444_CR3","doi-asserted-by":"crossref","unstructured":"Iihara H, Abe M, Wada M, Iino K, Akechi T, Imamura C, et al. 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol. 2024;29:873-8.","DOI":"10.1007\/s10147-024-02535-x"},{"key":"444_CR4","doi-asserted-by":"crossref","unstructured":"Do\u011fan N, Pekdemir M, Y\u0131lmaz S, et al. Intravenous metoclopramide in the treatment of acute migraines: A randomized, placebo-controlled trial. Acta Neurol Scand. 2019;139:334-9.","DOI":"10.1111\/ane.13063"},{"key":"444_CR5","doi-asserted-by":"crossref","unstructured":"Uchida T, Ogawa Y, Kobayashi Y, Ishikawa T, Ohashi H, Hata T, et al. Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Sci. 2011;102(9):1680-6.","DOI":"10.1111\/j.1349-7006.2011.01993.x"},{"key":"444_CR6","unstructured":"NCCN. Clinical Practice Guidelines in Oncology- Myelodysplastic Syndromes Version 1. 2025. Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf Accessed 20 Nov 2024."},{"key":"444_CR7","unstructured":"NCCN. Clinical Practice Guidelines in Oncology-Acute Myeloid Leukemia Version 3. 2024. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf Accessed 20 Nov 2024."},{"key":"444_CR8","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al: Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383:617\u2009\u2212\u200929.","DOI":"10.1056\/NEJMoa2012971"},{"key":"444_CR9","unstructured":"NCCN. Clinical Practice Guidelines in Oncology-Antiemesis-Version 2 2024. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf Accessed 20 Nov 2024."},{"key":"444_CR10","doi-asserted-by":"crossref","unstructured":"Takeuchi H, Saeki T, Aiba K, et al. Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. Int J Clin Oncol. 2016;21:1\u201312.","DOI":"10.1007\/s10147-015-0852-1"},{"key":"444_CR11","doi-asserted-by":"crossref","unstructured":"Gupta K, Walton R, Kataria SP: Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends. Cancer Treat Res Commun. 2021; 26:100278.","DOI":"10.1016\/j.ctarc.2020.100278"},{"key":"444_CR12","doi-asserted-by":"crossref","unstructured":"Marty M, Pouillart P, Scholl S, et al: Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990; 322:816\u2009\u2212\u200921.","DOI":"10.1056\/NEJM199003223221205"},{"key":"444_CR13","unstructured":"Gareth JS. Metoclopramide: A Template for Drug Discovery. J Drug Des Res. 2017;4(1):1031."},{"key":"444_CR14","doi-asserted-by":"crossref","unstructured":"Gralla RJ, Itri LM, Pisko SE, et al: Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981; 305:905-9.","DOI":"10.1056\/NEJM198110153051601"},{"key":"444_CR15","doi-asserted-by":"crossref","unstructured":"Sekine I, Segawa Y, Kubota K, et al. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci. 2013;104:711-7.","DOI":"10.1111\/cas.12146"},{"key":"444_CR16","doi-asserted-by":"crossref","unstructured":"Warr DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer. 2011;19:807\u2009\u2212\u200913.","DOI":"10.1007\/s00520-010-0899-5"},{"key":"444_CR17","doi-asserted-by":"crossref","unstructured":"Yano S, Makino K, Nakamura H, et al: Comparative clinical study of the anti-emetic effects of oral ramosetron and injected granisetron in patients with malignant glioma undergoing ACNU chemotherapy. Neurol Med Chir (Tokyo). 2005;45:294-8.","DOI":"10.2176\/nmc.45.294"},{"key":"444_CR18","doi-asserted-by":"crossref","unstructured":"Machu TK: Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. Pharmacol Ther. 2011;130:338\u2009\u2212\u200947.","DOI":"10.1016\/j.pharmthera.2011.02.003"},{"key":"444_CR19","doi-asserted-by":"crossref","unstructured":"Pinarli FG, Elli M, Dagdemir A, et al: Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer. Pediatr Blood Cancer. 2006;47:567\u2009\u2212\u200971.","DOI":"10.1002\/pbc.20639"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00444-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00444-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00444-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T15:58:47Z","timestamp":1745510327000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-025-00444-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["444"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00444-3","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Shiga University of Medical Science (approval number R2023-025). Informed consent was waived due to the retrospective nature of the study. We conducted an opt-out procedure on the website to disclose the research content and provide patients with the opportunity to decline.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}